Oncotarget

Research Papers:

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer

Bo Ai _, Huiquan Liu, Yu Huang and Ping Peng

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:44583-44595. https://doi.org/10.18632/oncotarget.10069

Metrics: PDF 1546 views  |   HTML 1457 views  |   ?  


Abstract

Bo Ai1, Huiquan Liu2, Yu Huang2, Ping Peng2

1Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan 430030, People’s Republic of China

2Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, Wuhan 430030, People’s Republic of China

Correspondence to:

Ping Peng, email: pengpingtjh@163.com

Keywords: circulating cell-free DNA, non-small cell lung cancer, prognosis, biomarker, meta-analysis

Received: February 28, 2016     Accepted: May 29, 2016     Published: June 15, 2016

ABSTRACT

Circulating cell-free DNA (cfDNA), which can be obtained from plasma or serum by non-invasive procedures, has showed great potential to predict treatment response and survival for cancer patients. Several studies have assessed the prognostic and predictive value of cfDNA in non-small cell lung cancer (NSCLC). However, these studies were often small and reported varying results. To address this issue, a meta-analysis was carried out. A total of 22 studies involving 2518 patients were subjected to the final analysis. Our results indicated that NSCLC patients with higher cfDNA concentration had shorter median progression-free survival (PFS) and overall survival (OS) time. In addition, high levels of cfDNA were significantly associated with poor PFS (hazard ratio or HR, 1.32; 95% CI, 1.02-1.71) and OS (HR, 1.64; 95% CI, 1.26-2.15). With respect to tumor specific mutations, we failed to reveal significant differences for PFS (HR, 1.30; 95% CI, 0.66-2.56) and OS (HR, 1.05; 95% CI, 0.49-2.25) when NSCLC patients were grouped according to KRAS genotype detected in cfDNA. However, NSCLC patients which harbored EGFR activating mutation in cfDNA had a greater chance of response to EGFR-TKIs (odds ratio or OR, 1.96; 95% CI, 1.59-2.42). No significant publication bias was detected in this study. In conclusion, cfDNA could act as a prognostic and predictive biomarker for patients with NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10069